CLOPIDOGREL Drug Interactions
Also known as: Clopidogrel
CLOPIDOGREL (brand name: Clopidogrel) is a Antiplatelet Agents. 1 INDICATIONS & USAGE Clopidogrel is a P2Y 12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS (unstable angina [UA]/non-ST-elevation myocardial infarction [NSTEMI]), clopidogrel has been shown to reduce the rate of myocardial infarction…CLOPIDOGREL has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Combining naproxen with clopidogrel significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided.
Mechanism
Naproxen, an NSAID, inhibits cyclooxygenase-1 (COX-1), reducing prostaglandin synthesis and impairing platelet aggregation. Clopidogrel is an antiplatelet agent that irreversibly blocks the P2Y12 receptor on platelets, preventing platelet activation and aggregation. The concurrent use of these agents results in an additive antiplatelet effect, significantly increasing the risk of bleeding.
Clinical Management
The primary clinical effect is a substantially elevated risk of bleeding, particularly gastrointestinal bleeding, which can be severe or life-threatening. Studies indicate that the combination of NSAIDs with antiplatelets can increase the risk of upper GI bleeding by 3-5 times compared to antiplatelet therapy alone. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, patients should be closely monitored for signs of bleeding (e.g., black stools, easy bruising, nosebleeds). Consider alternative pain management strategies or gastroprotective agents (e.g., proton pump inhibitors) if NSAID use is essential. Evaluate the need for both medications carefully.
Taking etodolac with clopidogrel significantly increases your risk of bleeding, especially in the stomach or intestines. This combination should generally be avoided.
Mechanism
Etodolac, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Clopidogrel is an antiplatelet agent that irreversibly inhibits the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation. The combined antiplatelet effects of both drugs lead to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), but also epistaxis, hematuria, and bruising. The risk of major GI bleeding with NSAID plus antiplatelet therapy can be several-fold higher compared to either drug alone. This combination should generally be avoided due to the high bleeding risk. If an NSAID is absolutely necessary, consider a COX-2 selective NSAID with a proton pump inhibitor (PPI) for gastroprotection, and monitor closely for signs of bleeding. Evaluate alternative pain management strategies that do not involve NSAIDs, such as acetaminophen or opioids, if appropriate.
Combining aspirin and clopidogrel significantly increases your risk of bleeding, especially from the stomach or intestines. Your doctor will weigh the benefits of preventing blood clots against this serious bleeding risk.
Mechanism
Both aspirin and clopidogrel inhibit platelet aggregation through different pathways, leading to a synergistic antiplatelet effect. Aspirin irreversibly inhibits cyclooxygenase (COX-1), reducing thromboxane A2 production, while clopidogrel is a prodrug that irreversibly blocks the P2Y12 ADP receptor on platelets. This dual inhibition severely impairs the body's ability to form clots.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding, which can be severe or even fatal. Studies have shown that dual antiplatelet therapy (DAPT) with aspirin and clopidogrel increases the risk of major bleeding by 50-100% compared to clopidogrel alone, and significantly higher than aspirin alone. This includes an elevated risk of intracranial hemorrhage. This combination should be used with extreme caution and only when the benefits of preventing thrombotic events (e.g., after stent placement) clearly outweigh the bleeding risks. Patients should be closely monitored for signs of bleeding (e.g., black/tarry stools, unusual bruising, nosebleeds). Proton pump inhibitors (PPIs) may be co-administered to reduce GI bleeding risk. The duration of DAPT should be as short as clinically necessary.
Combining ibuprofen with clopidogrel significantly increases your risk of bleeding, especially in the stomach or intestines. Your doctor may need to adjust your medications or monitor you closely.
Mechanism
Ibuprofen, an NSAID, inhibits cyclooxygenase (COX) enzymes, leading to reduced prostaglandin synthesis and impaired platelet aggregation. Clopidogrel is an antiplatelet agent that irreversibly blocks the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation. The concurrent use of both drugs results in additive antiplatelet effects, profoundly increasing the risk of bleeding.
Clinical Management
Patients taking both ibuprofen and clopidogrel face a substantially elevated risk of serious bleeding events, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other systemic bleeding. The risk of major GI bleeding can be several-fold higher compared to either drug alone. Symptoms may include black or tarry stools, blood in vomit, prolonged bleeding from cuts, or unexplained bruising. Concurrent use should generally be avoided due to the high bleeding risk. If an NSAID is absolutely necessary, consider alternatives with lower GI risk like celecoxib, or topical NSAIDs, for the shortest duration possible. Close monitoring for signs of bleeding is crucial, and proton pump inhibitor (PPI) co-administration should be considered to reduce GI bleeding risk. Re-evaluate the necessity of both agents and consider alternative pain management strategies.
Combining indomethacin with clopidogrel significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided due to the heightened risk of serious bleeding events.
Mechanism
Both indomethacin (an NSAID) and clopidogrel (an antiplatelet) inhibit platelet aggregation through different mechanisms, leading to an additive antiplatelet effect. Indomethacin also causes direct gastrointestinal mucosal damage and inhibits prostaglandin synthesis, which normally protects the GI lining, further increasing the risk of bleeding.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other systemic bleeding events. Studies show that combining NSAIDs with antiplatelets can increase the risk of upper GI bleeding by 3 to 15 times compared to either drug alone. This combination should generally be avoided. If concomitant use is unavoidable, patients require very close monitoring for signs of bleeding (e.g., black stools, easy bruising, nosebleeds). Consider alternative pain management strategies or a proton pump inhibitor (PPI) for gastroprotection if the NSAID is absolutely necessary. Re-evaluate the need for both medications frequently.
Combining celecoxib with clopidogrel significantly increases your risk of bleeding, especially in the stomach or intestines. You should avoid taking these medications together unless specifically directed by your doctor.
Mechanism
Celecoxib, an NSAID, inhibits prostaglandin synthesis, which can impair gastric mucosal defense and platelet aggregation. Clopidogrel is an antiplatelet agent that irreversibly inhibits the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation. The combined antiplatelet effects and gastric irritation from celecoxib lead to an additive increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), but also bruising, nosebleeds, and other hemorrhagic events. Studies show a significantly higher risk of major bleeding events when NSAIDs are co-administered with antiplatelets, potentially increasing risk by 2-4 times compared to antiplatelet monotherapy. Concomitant use of celecoxib and clopidogrel should generally be avoided due to the high bleeding risk. If co-administration is deemed absolutely necessary by a physician, use the lowest effective dose of celecoxib for the shortest duration possible, and consider gastroprotective agents (e.g., proton pump inhibitors). Closely monitor for any signs of bleeding, such as black tarry stools, unusual bruising, or persistent nosebleeds. Alternative pain management strategies should be explored.
Combining piroxicam with clopidogrel significantly increases your risk of bleeding, particularly in the stomach or intestines. This combination should generally be avoided due to severe potential harm.
Mechanism
Piroxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Clopidogrel is an antiplatelet agent that irreversibly inhibits the P2Y12 ADP receptor on platelets, preventing platelet activation. The concurrent use of these agents results in a synergistic inhibition of platelet function and disruption of gastrointestinal mucosal defense, leading to a substantially heightened risk of bleeding.
Clinical Management
The primary clinical effect is a significantly increased risk of serious bleeding, including gastrointestinal hemorrhage (e.g., ulcers, melena, hematemesis), intracranial hemorrhage, and other major bleeding events. The risk of major gastrointestinal bleeding can be increased by 3 to 15 times compared to either drug alone, with a particularly high risk in the elderly or those with a history of GI issues. This combination is generally contraindicated. If concurrent use is unavoidable, it should be for the shortest duration possible, with close monitoring for signs of bleeding (e.g., black stools, easy bruising, unusual fatigue). Consider alternative pain management strategies that do not involve NSAIDs, or alternative antiplatelet agents if appropriate. Proton pump inhibitor (PPI) co-therapy should be considered if the combination is absolutely necessary to reduce GI bleeding risk.
Combining meloxicam with clopidogrel significantly increases your risk of bleeding, especially in the stomach and intestines. This combination should generally be avoided.
Mechanism
Meloxicam, a non-steroidal anti-inflammatory drug (NSAID), inhibits prostaglandin synthesis, which can impair platelet function and disrupt the protective gastric mucosal barrier. Clopidogrel is an antiplatelet agent that irreversibly blocks the P2Y12 ADP receptor on platelets, preventing their aggregation. The concurrent use leads to additive antiplatelet effects and increased gastrointestinal damage, significantly elevating bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), which can be severe or even fatal. Symptoms may include black, tarry stools; vomiting blood; or unusual bruising. The risk of major GI bleeding with NSAID plus antiplatelet therapy is significantly elevated compared to either drug alone. This combination should be avoided if possible. If concomitant use is unavoidable, patients should be closely monitored for signs of bleeding, and a proton pump inhibitor (PPI) should be co-prescribed to reduce GI bleeding risk. Consider alternative pain management strategies or alternative antiplatelet agents if appropriate, and discuss with a healthcare provider.
Combining diclofenac with clopidogrel significantly increases your risk of bleeding, especially from the stomach or intestines. This combination should generally be avoided.
Mechanism
Diclofenac, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis which protects the gastrointestinal lining and also impairs platelet aggregation. Clopidogrel is an antiplatelet agent that irreversibly inhibits the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation. The concurrent use of these agents results in additive antiplatelet effects and increased gastrointestinal mucosal damage, leading to a synergistic increase in bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of serious bleeding, including gastrointestinal bleeding (e.g., ulcers, hemorrhage), intracranial hemorrhage, and other systemic bleeding events. Studies indicate that the combination of NSAIDs and antiplatelets can increase the risk of upper gastrointestinal bleeding by several-fold compared to either drug alone. This combination should generally be avoided due to the high bleeding risk. If concurrent use is unavoidable, patients must be closely monitored for signs of bleeding (e.g., black/tarry stools, unusual bruising, blood in urine/stools). Consider alternative pain management strategies that do not involve NSAIDs, or use the lowest effective dose of diclofenac for the shortest duration possible, along with gastroprotective agents like proton pump inhibitors.
Combining ketorolac with clopidogrel significantly increases your risk of serious bleeding, including stomach bleeding, which can be life-threatening. Your doctor will likely avoid this combination.
Mechanism
Ketorolac, a non-steroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis and impairing platelet aggregation. Clopidogrel is an antiplatelet agent that irreversibly blocks the P2Y12 ADP receptor on platelets, preventing platelet activation and aggregation. The concurrent use of these agents leads to a synergistic inhibition of platelet function, significantly increasing bleeding risk.
Clinical Management
The primary clinical effect is a substantially increased risk of bleeding, particularly gastrointestinal bleeding (e.g., ulcers, hemorrhage), but also bleeding from other sites. Studies indicate that the risk of major bleeding can be 3 to 15 times higher when NSAIDs are combined with antiplatelets compared to antiplatelets alone, with a specific concern for upper gastrointestinal bleeding. Symptoms may include black, tarry stools, vomiting blood, or unusual bruising. This combination should generally be avoided due to the high risk of serious bleeding. If an NSAID is absolutely necessary, consider alternative pain management strategies or a COX-2 selective NSAID (like celecoxib) for the shortest duration possible, though even these carry increased risk. Closely monitor for any signs of bleeding (e.g., melena, hematemesis, petechiae, unexplained bruising). Proton pump inhibitors (PPIs) may be co-prescribed to reduce gastrointestinal bleeding risk if the combination is unavoidable, but this does not eliminate the risk.
For complete prescribing information:
View full CLOPIDOGREL monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.